South Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase 3 trial, but the company reckons it doesn’t spell the end of the programme.

Harrington was lead investigator on the pivotal trial of T-Vec, the first oncolytic virus approved in the USA. PsiVac plans to test Ixovex-1 in combination with another drug, possibly a checkpoint ...

The global oncolytic virus cancer therapy market is poised for exceptional growth, expanding from an estimated USD 36.87 million in 2025 to an impressive USD 386.89 million by 2035, marking a Compound ...

Bacillus Calmette-Guérin (BCG) remains the primary treatment for patients with high-risk bladder cancer, but resistance develops in 30% to 40% of cases. The use of oncolytic viruses has emerged as a ...

As per Vantage Market Research, the Global Oncolytic Virus Immunotherapy Market has been significantly growing over the years due to the increasing prevalence of cancer and the adoption of advanced ...